Back

microRNA-17-5p and microRNA-20a-5p downregulation by atorvastatin in Hepg2 cells: a new mechanism involved in the lipid-lowering therapy

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Mechanisms underlying pharmacotherapy Lipid-Lowering Agents ESC Premium Access ESC Congress 2019

About the speaker

Photo
Assistant Professor Kathleen Saavedra

University of La Frontera, Temuco (Chile)

6 More presentations in this session

Presentation thumbnail
Chronic administration of Empagliflozin induces cardioprotection in vivo in absence of diabetes mellitus
Doctor P. Nikolaou (Athens, GR)
Abstract Slides
Presentation thumbnail
Atorvastatin and fenofibrate exert opposite effects on the vascularization and characteristics of visceral adipose tissue
Doctor O. Perez-Mendez (Mexico City, MX)
Abstract Slides
Presentation thumbnail
The pineal hormone melatonin inhibits doxorubicin-induced mitochondrial dysfunction and apoptosis in cardiomyocytes
Miss T. Kasi Ganeshan (London, GB)
Abstract
Presentation thumbnail
Significative role of edoxaban on endotelial cell functions
Miss C. Almenglo (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Acute Cardio-Selective Functional Modulation via a Small-Molecule Direct Myosin-Attenuator (MYK-581) Preserves Diaphragmatic Function in vivo: Comparison versus Disopyramide
Doctor C. del Rio (Brisbane, US)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Mechanisms underlying pharmacotherapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources